[Translation] A randomized, double-blind, placebo-controlled, parallel-group phase II clinical trial to preliminarily evaluate the efficacy and safety of STC007 injection in treating chronic kidney disease-related pruritus in patients undergoing hemodialysis.

主要目的：评价不同剂量STC007注射液连续给药12周在接受血液透析的中至重度慢性肾脏病相关性瘙痒患者中的初步有效性，探索可能的Ⅲ期给药剂量。次要目的：初步评价不同剂量STC007注射液连续给药12周在接受血液透析的中至重度慢性肾脏病相关性瘙痒患者中的安全性。探索性评价不同剂量STC007注射液的药代动力学（PK）特征。探索性评价不同剂量STC007注射液连续给药12周后停药1周在接受血液透析的中至重度慢性肾脏病相关性瘙痒患者中的躯体依赖性。

[Translation]

Primary Objective: To evaluate the preliminary efficacy of different doses of STC007 injection administered continuously for 12 weeks in patients with moderate to severe chronic kidney disease-related pruritus undergoing hemodialysis, and to explore possible phase III dosage. Secondary Objective: To preliminarily evaluate the safety of different doses of STC007 injection administered continuously for 12 weeks in patients with moderate to severe chronic kidney disease-related pruritus undergoing hemodialysis. To explore the pharmacokinetic (PK) characteristics of different doses of STC007 injection. To explore the physical dependence of different doses of STC007 injection administered continuously for 12 weeks followed by a 1-week discontinuation in patients with moderate to severe chronic kidney disease-related pruritus undergoing hemodialysis.

Start Date03 Apr 2026

Sponsor / Collaborator

Chengdu Nuohe Shengtai Biotechnology Co., Ltd.

CTR20241332

/ CompletedPhase 2

初步评估 STC007 注射液治疗腹部手术后疼痛的有效性、安全性和药代动力学特征的随机、双盲、安慰剂/阳性对照Ⅱ期临床研究

[Translation] A randomized, double-blind, placebo/active-controlled Phase II clinical study to preliminarily evaluate the efficacy, safety and pharmacokinetic characteristics of STC007 injection in the treatment of postoperative pain in abdominal surgery

与安慰剂和阳性对照药比较，初步评价STC007注射液不同剂量下治疗腹部手术后疼痛的有效性，探索STC007注射液用于腹部术后镇痛的合理剂量。

[Translation]

Compared with placebo and positive control drugs, the effectiveness of STC007 injection at different doses in treating pain after abdominal surgery was preliminarily evaluated, and the reasonable dose of STC007 injection for abdominal postoperative analgesia was explored.

Start Date28 Oct 2024

Sponsor / Collaborator

Chengdu Nuohe Shengtai Biotechnology Co., Ltd.

CTR20240648

/ CompletedPhase 1

评估STC007注射液在接受血液透析的中至重度慢性肾病相关性瘙痒患者中多次给药的安全性、耐受性、PK及PD特征的Ib期临床研究

[Translation] A Phase Ib clinical study to evaluate the safety, tolerability, PK and PD characteristics of STC007 injection after multiple doses in patients with moderate to severe chronic kidney disease-related pruritus undergoing hemodialysis

主要目的：与同等剂量KAPRUVIA™（difelikefalin）注射液比较，评估一周内多次给予0.5μg/kg STC007注射液在接受血液透析的中至重度慢性肾脏病相关性瘙痒患者中的PK及PD特征。次要目的：评价一周内多次给予0.5μg/kg STC007注射液在接受血液透析的中至重度慢性肾脏病相关性瘙痒患者中的安全性、耐受性。

[Translation]

Primary objective: Compared with the same dose of KAPRUVIA™ (difelikefalin) injection, evaluate the PK and PD characteristics of 0.5μg/kg STC007 injection given multiple times a week in patients with moderate to severe chronic kidney disease-related pruritus undergoing hemodialysis. Secondary objective: Evaluate the safety and tolerability of 0.5μg/kg STC007 injection given multiple times a week in patients with moderate to severe chronic kidney disease-related pruritus undergoing hemodialysis.

Start Date10 Apr 2024

Sponsor / Collaborator

Chengdu Nuohe Shengtai Biotechnology Co., Ltd.

100 Clinical Results associated with STC007

100 Translational Medicine associated with STC007

100 Patents (Medical) associated with STC007

100 Deals associated with STC007

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Kidney Disease-Associated Pruritus	Phase 2	China	Chengdu Nuohe Shengtai Biotechnology Co., Ltd.	03 Apr 2026
Pain, Postoperative	Phase 2	China	Chengdu Nuohe Shengtai Biotechnology Co., Ltd.	28 Oct 2024
Chronic nephritis	Phase 1	China	Chengdu Nuohe Shengtai Biotechnology Co., Ltd.	22 Jun 2026
Chronic Kidney Diseases	Phase 1	China	Chengdu Nuohe Shengtai Biotechnology Co., Ltd.	17 May 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis